Matching slides 42,534
Current window 30,001-30,030
Pages 1,418
Rows per page 30
Beat: Resolutionclear collectionreset all

Beat

30,001-30,030 of 42,534

filter-aware
11
The slide uses a split layout with charts on the left and key takeaways on the right.Allego | Results Presentation Deck | 16 slides · Allego
Conference presentation Investor relations Beat · ActionLoop · Quick Win Big Bet1 hit
12
The slide uses a split layout with charts on the left and key takeaways on the right.Allego | Results Presentation Deck | 16 slides · Allego
Conference presentation Investor relations Beat · ActionLoop · Quick Win Big Bet1 hit
13
Allego | Results Presentation Deck | 16 slidesAllego | Results Presentation Deck | 16 slides · Allego
Conference presentation Investor relations Beat · ActionLoop · Quick Win Big Bet1 hit
14
Allego | Results Presentation Deck | 16 slidesAllego | Results Presentation Deck | 16 slides · Allego
Conference presentation Investor relations Beat · Action1 hit
15
The table provides a bridge between statutory loss and non-IFRS metrics like EBITDA and Free Cash Flow.Allego | Results Presentation Deck | 16 slides · Allego
Conference presentation Investor relations Beat · Action1 hit
16
Allego | Results Presentation Deck | 16 slidesAllego | Results Presentation Deck | 16 slides · Allego
Conference presentation Investor relations Beat · Action1 hit
26
Includes spider plot (target lesion change over time) and waterfall plot (best percentage change).AstraZeneca | Investor Event Presentation Deck | 52 slides · AstraZeneca
Conference presentation Investor relations Beat · Action1 hit
27
The slide uses a matrix-like layout to categorize clinical trials by disease stage and treatment line.AstraZeneca | Investor Event Presentation Deck | 52 slides · AstraZeneca
Conference presentation Investor relations Beat · Action1 hit
28
The slide uses a matrix structure to segment the market by disease stage and molecular profile, overlaying clinical trial names (e.g., AEGEAN, FLAURA) as product markers.AstraZeneca | Investor Event Presentation Deck | 52 slides · AstraZeneca
Conference presentation Investor relations Beat · Action1 hit
29
AstraZeneca | Investor Event Presentation Deck | 52 slidesAstraZeneca | Investor Event Presentation Deck | 52 slides · AstraZeneca
Conference presentation Investor relations Beat · Action1 hit
30
AstraZeneca | Investor Event Presentation Deck | 52 slidesAstraZeneca | Investor Event Presentation Deck | 52 slides · AstraZeneca
Conference presentation Investor relations Beat · Action1 hit
31
The slide uses a standard clinical trial flow diagram (process flow).AstraZeneca | Investor Event Presentation Deck | 52 slides · AstraZeneca
Conference presentation Investor relations Beat · Action1 hit
32
Clinical trial data presentation showing PFS outcomes for Arm 1 (chemo + bev) vs Arm 3 (chemo + bev + durvalumab + olaparib).AstraZeneca | Investor Event Presentation Deck | 52 slides · AstraZeneca
Conference presentation Investor relations Beat · Action1 hit
33
Clinical trial data presentation using Kaplan-Meier plots with associated risk tables and hazard ratios.AstraZeneca | Investor Event Presentation Deck | 52 slides · AstraZeneca
Conference presentation Investor relations Beat · Action1 hit
34
The chart is a radial segment diagram showing patient population segments (HRD-negative, HRD-positive non-BRCAm, tBRCAm) and corresponding clinical trials.AstraZeneca | Investor Event Presentation Deck | 52 slides · AstraZeneca
Conference presentation Investor relations Beat · Action1 hit
35
The slide outlines the clinical trial methodology, specifically the randomization and treatment arms for advanced endometrial cancer.AstraZeneca | Investor Event Presentation Deck | 52 slides · AstraZeneca
Conference presentation Investor relations Beat · Action1 hit
36
The slide features headshots of the two presenters and a scientific illustration of the drug mechanism.AstraZeneca | Investor Event Presentation Deck | 52 slides · AstraZeneca
Conference presentation Investor relations Beat · Action1 hit
37
The slide outlines a basket trial design for Enhertu across multiple solid tumor types.AstraZeneca | Investor Event Presentation Deck | 52 slides · AstraZeneca
Conference presentation Investor relations Beat · Action1 hit
38
The table uses color-coded headers for different tumor types. The 'Best overall response' section is highlighted with a yellow border.AstraZeneca | Investor Event Presentation Deck | 52 slides · AstraZeneca
Conference presentation Investor relations Beat · Action1 hit
39
The slide includes a summary table at the bottom showing Median Duration of Response (DoR) for the three patient cohorts.AstraZeneca | Investor Event Presentation Deck | 52 slides · AstraZeneca
Conference presentation Investor relations Beat · Action1 hit
40
The chart is a classic waterfall plot used in oncology clinical trials to visualize tumor shrinkage.AstraZeneca | Investor Event Presentation Deck | 52 slides · AstraZeneca
Conference presentation Investor relations Beat · Action1 hit
41
The chart uses a grouped bar structure to compare IHC 3+ and IHC 2+ prevalence ranges across 8 cancer types.AstraZeneca | Investor Event Presentation Deck | 52 slides · AstraZeneca
Conference presentation Investor relations Beat · Action1 hit
42
Includes a headshot of the speaker and a medical illustration of blood cells/DNA.AstraZeneca | Investor Event Presentation Deck | 52 slides · AstraZeneca
Conference presentation Investor relations Beat · Action1 hit
43
The slide illustrates the process of reweighting the ASCEND trial population to match the ALPINE trial population for a fair comparison.AstraZeneca | Investor Event Presentation Deck | 52 slides · AstraZeneca
Conference presentation Investor relations Beat · Action1 hit
44
The slide uses a Kaplan-Meier curve for PFS and a forest plot for safety odds ratios.AstraZeneca | Investor Event Presentation Deck | 52 slides · AstraZeneca
Conference presentation Investor relations Beat · Action1 hit
45
The slide is divided into two sections: Executive Leadership and Therapeutic Area Leadership.AstraZeneca | Investor Event Presentation Deck | 52 slides · AstraZeneca
Conference presentation Investor relations Beat · Action1 hit
46
The slide uses a column-based layout to map specific drug brands and pipeline assets to five major oncology therapeutic areas.AstraZeneca | Investor Event Presentation Deck | 52 slides · AstraZeneca
Conference presentation Investor relations Beat · Action1 hit
47
AstraZeneca | Investor Event Presentation Deck | 52 slidesAstraZeneca | Investor Event Presentation Deck | 52 slides · AstraZeneca
Conference presentation Investor relations Beat · Action1 hit
48
The slide uses a matrix-like structure to align patient segments (rows) with treatment stages (columns) and specific clinical trials (cells).AstraZeneca | Investor Event Presentation Deck | 52 slides · AstraZeneca
Conference presentation Investor relations Beat · Action1 hit
07
The slide compares previous vs updated guidance for FY 2023 and break-even targets.Talkspace | Results Presentation Deck | 11 slides · Talkspace
Conference presentation Investor relations Beat · ActionLoop · Cost Of Inaction1 hit